Dec 15 (Reuters) – The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson’s blood cancer treatment, bringing the total number of products receiving an award under the new program to 16 this year.
Launched in June, the FDA Commissioner’s National Priority Voucher program cuts the review timeline of drugs considered critical to public health or national security needs to just one to two months from the usual 10-12 months.
The FDA awarded the latest voucher to J&J’s experimental treatment, Tecvayli in combination with Darzalex, after it showed significant improvement over the standard of care in patients with multiple myeloma during a late-stage trial.
Last month, the FDA awarded the voucher to Novo Nordisk’s weight-loss drug Wegovy and Eli Lilly’s experimental obesity pill orforglipron.
(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
Comments